? Expanded (Regional) Pilot and Feasibility Program The specific aim of the Michigan Diabetes Research Center (MDRC) expanded Regional Pilot/Feasibility Study (P/F) Grants Program is to stimulate new research and collaboration in the areas of diabetes, its complications and related endocrine and metabolic disorders in the region. This research may be in areas of basic biomedical science or clinical research. This program will fund at least 2 P/F grants submitted by investigators from our three regional partners per year. A minimum of $100,000 per year will be provided by the MDRC and a minimum of an additional $20,000 per year will be provided through cost-sharing agreements with the University of Toledo, Michigan State University, and Wayne State University. Each year, the MDRC will solicit applications for grants from full-time instructional or research faculty at these three institutions. Those eligible include: 1) new investigators without current or past NIH research support who are beginning careers in diabetes research, 2) established investigators new to diabetes research who wish to focus their expertise on diabetes, and 3) established investigators who propose innovative research in diabetes that represents a clear departure from their ongoing research. Applications are peer-reviewed by at least two extramural investigators with expertise in the area of the application. Those with merit, as judged by this review process and the Grants Program Advisory Council, which includes representatives from the three regional partner universities, will receive P/F awards. The ultimate goal of the grant program is to enhance communication and collaboration among regional diabetes researchers, accelerate the pace of research, and enable awardees to generate sufficient preliminary data for successful applications for major research funding from the NIH or other national granting agencies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK020572-44
Application #
10071184
Study Section
Special Emphasis Panel (ZDK1)
Project Start
1996-12-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
44
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Sas, Kelli M; Lin, Jiahe; Rajendiran, Thekkelnaycke M et al. (2018) Shared and distinct lipid-lipid interactions in plasma and affected tissues in a diabetic mouse model. J Lipid Res 59:173-183
Adams, Jessica M; Pei, Hongjuan; Sandoval, Darleen A et al. (2018) Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons. Diabetes 67:1538-1548
Fernandez, Carmen; DeJesus, Jasmine M; Miller, Alison L et al. (2018) Selective eating behaviors in children: An observational validation of parental report measures. Appetite 127:163-170
Zhang, Sherry; Lu, Chunxia; Das, Arun K et al. (2018) Abrogation of GH action in Kupffer cells results in increased hepatic CD36 expression and exaggerated nonalcoholic fatty liver disease. Growth Horm IGF Res 42-43:74-79
Mishra, Manish; Duraisamy, Arul J; Kowluru, Renu A (2018) Sirt1: A Guardian of the Development of Diabetic Retinopathy. Diabetes 67:745-754
Jaiswal, Mamta; Divers, Jasmin; Urbina, Elaine M et al. (2018) Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth Cohort Study. Pediatr Diabetes 19:680-689
Rios, Peter D; Skoumal, Michael; Liu, Jeffrey et al. (2018) Evaluation of encapsulating and microporous nondegradable hydrogel scaffold designs on islet engraftment in rodent models of diabetes. Biotechnol Bioeng 115:2356-2364
Zhang, Peng; Kuang, Henry; He, Yanlin et al. (2018) NRG1-Fc improves metabolic health via dual hepatic and central action. JCI Insight 3:
Rosenstock, Julio; Perkovic, Vlado; Alexander, John H et al. (2018) Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardi Cardiovasc Diabetol 17:39
Kady, Nermin M; Liu, Xuwen; Lydic, Todd A et al. (2018) ELOVL4-Mediated Production of Very Long-Chain Ceramides Stabilizes Tight Junctions and Prevents Diabetes-Induced Retinal Vascular Permeability. Diabetes 67:769-781

Showing the most recent 10 out of 1823 publications